The use of burosumab may be clinically supported in patients with persistent FGF23-mediated hypophosphatemia who necessitate recurrent exposure to intravenous iron formulations and are unable to be effectively managed with conventional therapy. Here, FGF23 is linked to hypophosphatemia.